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ABSTRACT
Mitragyna speciosa Korth., also known as ketum or kratom, is a tropical plant native to 
Southeast Asia. Mitragynine is its major active alkaloid. It is traditionally used as treatment 
for various conditions, including fever. The crude extract of M. speciosa leaves has been 
proven to have anti-inflammatory and analgesic properties. In general, M. speciosa induces 
a dose-dependent effect, inducing a stimulant effect at low dose and an opioid-like effect at 
a high dose. This study was conducted to determine the antipyretic effect of mitragynine 
and methanolic extract of M. speciosa (MSM) using mice as an in vivo pyretic model. 
Eighty mice were divided into 8 groups: 6 treatment groups (mitragynine: 5, 10, and 20 
mg/kg; MSM: 50, 100, and 200 mg/kg) and 2 control groups (20% Tween 80 in 0.9% NaCl; 
ketoprofen 1 mg/kg). Eighteen hours after induction of pyrexia by inoculation of yeast, rectal 
temperature was measured every half an hour for 5 hours. Compared to the negative control 
group, all groups treated with either mitragynine or MSM had significant reduction of rectal 
temperature at different points of time. The positive control group treated with ketoprofen 
had significant (P < 0.001) reduction of pyrexia from 0.5 to 5.0 hours after dosing. At 200 
mg/kg, MSM has led to the opioid-like effect of hypothermia, possibly due to its synergistic 
effect with other compounds such as 7-hydroxymitragynine or mitragynine pseudoindoxyl. 
This article discusses concerns pertaining to toxicity of mitragynine and MSM, and 
possible involvement of cyclooxygenase 
and microsomal prostaglandin E2 synthase 
pathways. In conclusion, mitragynine and 
MSM possess dose-dependent antipyretic 
properties in mice.
Keywords: Mitragyna speciosa, mitragynine, mice, 
pyrexia
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INTRODUCTION
Mitragyna speciosa Korth., also known as 
ketum or kratom, is a plant found in tropical 
and subtropical Asia (such as Thailand, 
Indonesia, and Malaysia), East and West 
Africa, and India (Ahmad & Aziz, 2012). 
In Malaysia, it is widely distributed across 
the northern half of Peninsular Malaysia and 
Selangor (Idayu et al., 2011). More than 40 
different alkaloids have been identified in the 
plant (Meireles et al., 2019). Mitragynine is 
regarded as the major alkaloid of the whole 
leaf, amounting to about 66.2% (Gibbons & 
Arunotayanun, 2013).
Asian workers use the leaves of M. 
speciosa for their stimulant effects (Saingam 
et al., 2013). The stimulant effect enhances 
the workers’ tolerance to endure heavy 
work and also relieves muscle strains. 
In Thailand and Malaysia, it is also used 
traditionally as treatment for fever (pyrexia), 
diarrhea, opium addiction, diabetes, and 
helminthiasis (Ahmad & Aziz, 2012). 
The leaves have been used to treat opium 
withdrawal syndrome and are considered as 
an alternative to methadone or other opioids 
(Prozialeck, 2016). Administration of M. 
speciosa usually results in dose-dependent 
effects. An opioid-like effect predominates 
at high doses, whereas administration at 
lower doses typically results in stimulant-
like effects.
Fever, or pyrexia, is an increase in 
body temperature above the normal range 
triggered by the presence of pyrogens. It 
can be caused by many infectious (e.g., 
bacterial, viral, parasitic diseases) or 
noninfectious (e.g., trauma, thrombosis, 
cancer) medical conditions. Hence, fever 
is the most common primary complaint in 
medical practices (Celebi et al., 2009). For 
humans, most antipyretic drugs are available 
as nonprescription drugs, including aspirin, 
acetaminophen, ibuprofen, ketoprofen, and 
naproxen. Although these antipyretic drugs 
are considered safe, adverse side effects have 
been reported that affect the gastrointestinal 
tract, kidney, and liver (Plaisance, 2000).
Scientifically, it has been shown that 
mitragynine and the crude methanolic 
extract of M. speciosa (MSM) provide anti-
inflammatory and antinociceptive properties 
by affecting the supraspinal opioid receptors 
(Meireles et al., 2019; Mossadeq et al., 2009). 
Most analgesic and anti-inflammatory drugs 
are known to possess antipyretic activity 
(Srinivasan et al., 2003). Since M. speciosa 
has been used traditionally as a treatment 
for fever, it is possible that it possesses 
an antipyretic effect. However, there is 
no scientific report available pertaining to 
such an effect of the crude extract of M. 
speciosa and mitragynine. Such information 
could be important for human or veterinary 
therapeutic uses in the future. This study 
was conducted to validate the traditional 
claim of the antipyretic effect of MSM 
and mitragynine using an in vivo pyretic 
mice model. Subsequently, the effective 
doses, onset of action, and duration of 
action related to the antipyretic effect were 
determined.
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MATERIALS AND METHODS
Preparation of Mitragynine and MSM
The study was conducted in 2010. MSM 
was obtained from freeze-dried stock 
of a previous study (Mossadeq et al., 
2009). The pure compound of mitragynine 
(Chromadex Inc., CA, USA) was purchased 
from Chemtron Biotechnology Sdn. Bhd. 
(Kuala Lumpur, Malaysia). Each substance 
was prepared in 20% Tween 80 in 0.9% 
NaCl (T-80-NaCl) (Idayu et al., 2011). This 
was achieved by dissolving them in 20 mL 
Tween 80 using a sonicator. The resulting 
solution was then mixed with 80 mL of 0.9% 
NaCl and stirred using a magnetic stirrer to 
produce a homogenous solution.
Animals
A total of 80 female BALB/c mice weighing 
between 20 and 25 g were obtained from 
the Animal Resource Unit, Faculty of 
Veterinary Medicine, Universiti Putra 
Malaysia. The animals were acclimatized 
for 2 weeks and kept in a standard cage at 
a stocking density of 8 mice per cage. They 
were housed in a laboratory animal facility 
with a 12-h light-dark cycle. The mice 
were brought to the laboratory and were 
acclimatized to the laboratory environment 
for 48 hours (h) prior to the experiment. All 
experimental procedures were approved 
by the Animal Care and Use Committee, 
Faculty of Veterinary Medicine, Universiti 
Putra Malaysia (FPV/AUP/FYP/009/2010).
Experimental Design and Antipyretic 
Effect
Evaluation of the antipyretic effect was 
conducted as previously described (Zakaria 
et al., 2008), with minor modifications. The 
basal temperature of all mice was measured 
using a digital thermometer by inserting 
a thermistor probe 1 cm into the rectum. 
Subsequently, the mice were induced into 
pyrexia by subcutaneous inoculation of 
30% (w/v) suspension of Brewer’s yeast 
in 0.9% NaCl at a dose of 10 mL/kg. 
Eighteen h after induction of pyrexia, rectal 
temperature was recorded. Because all 80 
mice had more than 0.5°C rise in rectal 
temperature, they were all subjected to the 
experiments. They were randomly divided 
into 8 groups. Groups 1, 2, and 3 were 
administered 5, 10, or 20 mg/kg mitragynine 
intraperitoneally (i.p.), respectively. Groups 
4, 5, and 6 were administered 50, 100, and 
200 MSM i.p., respectively. The different 
doses of mitragynine and MSM were 
based on a previous study that evaluated 
the antinociceptive properties of these 
substances (Sabetghadam et al., 2010). 
Group 7 was administered ketoprofen 1 
mg/kg i.p. as positive control, and mice of 
Group 8 were administered T-80-NaCl i.p. as 
a negative control. Rectal temperature was 
immediately measured after the treatment 
and every 30 minutes thereafter, for a total 
period of 5 h. Percentage of temperature 
reduction was calculated using the following 
formula:
Percentage of temperature reduction = yeast− induced pyrexia− post treatment temperatureyeast − induced pyrexia × 100
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Statistical Analysis
The mean change in the rectal temperature 
for each mouse was calculated. General 
linear model repeated measure analysis of 
variance (ANOVA) was used to analyze data 
separately between the groups treated with 
mitragynine and the groups treated with 
MSM. Results were expressed as mean ± 
standard error of the mean (SEM). One-
way ANOVA followed by posthoc analysis 
was used to compare data of the treatment 
and negative control groups at each point 
of time. All data were analyzed to observe 
different degrees of statistical significance 
(P < 0.05, P < 0.01, P < 0.001).
RESULTS
Mauchly’s test of sphericity, multivariate 
test, and test within subject from repeated 
measure ANOVA showed a significant (P < 
0.001) relationship between change in rectal 
temperature, time, treatment, and interaction 
between time and treatment. In between 
subjects, the rectal temperature was found 
to be significantly affected by the different 
types of treatment administered, while 
within subjects, the rectal temperature was 
significantly affected by the time.
Induction of pyrexia in negative control 
mice of Group 8 resulted in elevation of 
rectal temperature to 38°C. This pyretic 
state persisted throughout the 5 h duration, 
with the highest rectal temperature of 
38.67°C recorded at 1.0 h. In general, mice 
of all treatment groups showed significant 
reduction of rectal temperature compared 
to negative control mice of Group 8 at 
different points of time (Figures 1 and 2). 
Positive control mice of Group 7 showed 
significant (P < 0.001) difference in rectal 
temperature from 0.5 to 5.0 h compared to 
negative control mice of Group 8 (Figure 1). 
The same group had a significant reduction 
in rectal temperature between 0.5 and 1.0 
h, and between 3.5 and 5.0 h compared to 
Group 8 (Tables 1 and 2). The lowest rectal 
temperature achieved in the positive control 
mice of Group 7 treated with ketoprofen was 
36.65°C at 5.0 h.
Mitragynine administered at a dose 
of 5 mg/kg in Group 1 mice resulted in 
significant reduction in rectal temperature 
between 1.0 and 4.5 h. On the other hand, 
mice treated with mitragynine (10 mg/kg) 
in Group 2 showed significant reduction in 
rectal temperature between 1.0 and 5.0 h. 
Administration of mitragynine at a dose of 
20 mg/kg in mice of Group 3 led to a highly 
significant (P < 0.001) reduction of rectal 
temperature between 0.5 and 5.0 h.
Mice of Group 4 administered with 
MSM at a dose of 50 mg/kg showed 
statistically significant (P < 0.05, P < 0.01, 
P < 0.001) reductions of rectal temperature 
between 2.5 and 5.0 h. Mice of Group 5 
treated with MSM at a dose of 100 mg/kg 
had a significant (P < 0.05, P < 0.01, P < 
0.001) reduction in rectal temperature at 0.5 
h and between 2.0 and 5.0 h. Mice of Group 
6 treated with MSM at a dose of 200 mg/
kg had a significant (P < 0.001) reduction 
in rectal temperature between 0.5 and 5.0 h.
The administration of ketoprofen in mice 
of Group 7 resulted in the highest percentage 
of inhibition of pyrexia (Figures 1 and 2) at 
5.0 h. Among all the doses of mitragynine 
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Figure 1. Percentage reduction of fever with mitragynine administered intraperitoneally in Brewer’s yeast-
induced pyrexia in mice. (*P < 0.05, **P < 0.01, and ***P < 0.001 compared to the negative control)
Figure 2. Percentage reduction of fever with methanolic extract of Mitragyna speciosa (MSM) administered 
intraperitoneally in Brewer’s yeast-induced pyrexia in mice. (*P < 0.05, **P < 0.01, and ***P < 0.001 
compared to the negative control)
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administered in this experiment, the dose 
of 20 mg/kg in mice of Group 3 showed 
the highest percentage of temperature 
reduction, which occurred at 4.0 h (Table 
1). As for the groups treated with MSM i.p., 
the greatest percentage of reduction of rectal 
temperature was observed in mice of Group 
6 at 2.0 h. However, mice of this group 
showed hypothermia between 1.0 and 3.5 
h. In general, both mitragynine and MSM 
administered intraperitoneally produced a 
dose-dependent antipyretic effect.
DISCUSSION
In this study, both mitragynine and MSM 
administered i.p. were observed to possess 
antipyretic properties in mice. The results 
suggested that administration of mitragynine 
at a dose of 20 mg/kg is marginally a more 
effective antipyretic compared to ketoprofen. 
On the other hand, administration of MSM 
at 200 mg/kg resulted in significantly more 
antipyretic effect compared to ketoprofen, to 
the point of adverse effect to the host. This is 
further discussed in a later paragraph.
Based on the  pa t te rn  of  rec ta l 
temperatures throughout the 5 h study, 
it was observed that the onset of action 
of both mitragynine and MSM was 
rapid, approximately 0.5 to 1.0 h after 
administration. However, in terms of 
duration of action, both mitragynine and 
MSM only provided a short duration of 
antipyretic activity, approximately 3.5 to 
4.0 h. Ketoprofen provided a similarly rapid 
onset of action but with a longer duration of 
actions (Cossellu et al., 2019) compared to 
MSM and mitragynine.
Mitragynine and MSM were observed 
to possess dose-dependent antipyretic 
effects, where administration at high dose 
of either mitragynine or MSM resulted in 
a statistically significant degree of pyrexia 
inhibition over time. Based on the statistical 
analysis, and the fact that the temperature 
decreased from a pyretic state to normal, the 
effective antipyretic dose for mitragynine 
was found to be 20 mg/kg, and for MSM it 
was 100 mg/kg.
At the highest dose of 200 mg/kg tested 
in this study, MSM resulted in transient 
hypothermia of the mice, which lasted for 
2.5 h. This dose-dependent effect may be 
explained by the fact that MSM has opioid-
like effects at high doses (Babu et al., 2008). 
Hypothermia is a well-documented effect of 
opioids (Henderson-Redmond et al., 2016). 
This may be explained by a synergistic 
effect brought about by the presence of 
other compounds in MSM. This leads to a 
great reduction in body temperature, which 
subsequently leads to hypothermia. The 
synergistic effect could be more prominent 
compared to that of a single compound. A 
similar synergistic effect was previously 
postulated in assessment of analgesic 
properties of MSM (Reanmongkol et al., 
2007). It is also possible that hypothermia 
was due to the presence of another important 
alkaloid that acts on the opioid receptor, such 
as 7-hydroxymitragynine or mitragynine 
pseudoindoxyl. The 7-hydroxymitragynine 
possesses higher affinity and is 1000 times 
more potent than morphine, particularly 
to the µ-opioid receptors, despite there 
being less of it compared to mitragynine 
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(McCurdy & Scully, 2005). On the other 
hand, mitragynine pseudoindoxyl was 
previously found to be 35-fold more potent 
than morphine in inhibiting electrically 
stimulated ileum contraction (Adkins et 
al., 2011). This potent alkaloid may act 
agonistically at the µ-opioid receptors, 
which are present abundantly especially 
in the hypothalamus,  to affect  the 
thermoregulation system of the body. This 
can produce antipyretic effects at the first 
30 minutes post treatment, and then induce 
hypothermia.
Hypothermia after i.p. administration 
of 200 mg/kg MSM is an undesirable 
antipyretic effect related to MSM. Another 
undesirable effect that could be of concern 
is toxicity. Previously, a subchronic study 
concluded that mitragynine is relatively 
safe at doses of 1-10 mg/kg, but leads to a 
toxic effect at 100 mg/kg (Sabetghadam et 
al., 2013). In an acute toxicity study, rodents 
orally administered 1000 mg/kg of MSM 
exhibited a reversible effect, with hepato- 
and nephron-toxicity (Harizal et al., 2010). 
This is in agreement with the few reports 
pertaining to M. speciosa intoxication in 
humans (Domingo et al., 2017). In other 
reports, the role of mitragynine in human 
fatalities was not conclusive (Domingo et 
al., 2017; Holler et al., 2011). Although 
MSM and mitragynine have therapeutic 
potential, issues pertaining to toxicity and 
abuse of these substances require further 
clarification.
Yeas t - induced  hyper thermia  i s 
also known as “fever” or “pyrexia”. Its 
pathogenesis includes the presence of 
exogenous pyrogens. These will eventually 
evoke the host-activated macrophages and 
mast cells to produce pyrogenic cytokines 
that act on the hypothalamus to induce 
a fever response (Werner et al., 2006). 
These cytokines will trigger another 
important mediator of fever, PGE2 in the 
thermoregulatory center at the region of the 
preoptic nuclei of the anterior hypothalamus 
(Roth & Souza, 2001). PGE2 activates 
the endocrine, autonomic, and behavioral 
responses that lead to fever (Saper & 
Breder, 1994). PGE2 requires the action of 
cyclooxygenase (COX) and microsomal 
PGE synthase (mPGES). Ketoprofen 
is known to inhibit pyrexia partially by 
inhibition of the COX enzyme. Hence, 
it is possible that the modes of action of 
both mitragynine and MSM involve a 
mechanism similar to that of ketoprofen. 
However, more studies are needed to 
ascertain the antipyretic mechanism of 
action of mitragynine and MSM.
CONCLUSION
Both mitragynine and MSM possess a 
dose-dependent antipyretic effect, where 
i.p. administration of MSM results in 
an opioid-like effect. Effective doses to 
achieve a desirable antipyretic effect for 
mitragynine and MSM are 20 and 100 mg/
kg, respectively. The onset of the antipyretic 
effect of mitragynine and MSM is rapid, but 
the duration of the antipyretic effect is short.
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